Molecular biology of head and neck cancers

Deepa Philip; Vanita Noronha; Amit Joshi; Vijay Patil; Anant Ramaswamy; Anuradha Chougule; Kumar Prabhash

doi:10.4103/2347-8128.182856

REVIEW ARTICLE

Year : 2016 | Volume : 4 | Issue : 1 | Page : 16-22

Molecular biology of head and neck cancers

Deepa Philip, Vanita Noronha, Amit Joshi, Vijay Patil, Anant Ramaswamy, Anuradha Chougule, Kumar Prabhash
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India

Date of Web Publication

23-May-2016

Correspondence Address:
Vanita Noronha
Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai - 400 012, Maharashtra
India

Source of Support: None, Conflict of Interest: None

Check

DOI: 10.4103/2347-8128.182856

Abstract

Head and Neck cancers constitute a real challenge for oncologists across the globe, with one person dying every hour of every day. It can distort and disfigure the face, strip away the voice and rob one of his basic abilities to eat, drink and swallow. The psychosocial impact can be extremely devastating. From previously being considered a homogenous entity, it is now a well recognized fact that Head and Neck cancer is rightly called “Head and neck cancers” in view of their genetic and molecular heterogeneity despite sharing histological and etiological homogeneity. The present review discusses recent insights as well as established principles of the molecular biology of Head and Neck Cancers.

Keywords: Head and neck cancer, HPV, molecular biology

How to cite this article:
Philip D, Noronha V, Joshi A, Patil V, Ramaswamy A, Chougule A, Prabhash K. Molecular biology of head and neck cancers. J Head Neck Physicians Surg 2016;4:16-22

How to cite this URL:
Philip D, Noronha V, Joshi A, Patil V, Ramaswamy A, Chougule A, Prabhash K. Molecular biology of head and neck cancers. J Head Neck Physicians Surg [serial online] 2016 [cited 2023 Mar 30];4:16-22. Available from: https://www.jhnps.org/text.asp?2016/4/1/16/182856

Introduction

Head and neck cancers constitute a real challenge for oncologists across the globe, with one person dying every hour of every day. It can distort and disfigure the face, strip away the voice, and rob one of his basic abilities to eat, drink, and swallow. The psychosocial impact can be so devastating that Sir. Sigmund Freud, the father of modern psychiatry, who was diagnosed with oral cavity cancer in 1930's underwent 30 surgeries on him and finally died at a personal request of being euthanized by his physician. In this present chapter, we will discuss recent insights into the molecular biology of this malignancy.

Head and neck cancer is rightly called “Head and neck cancers” in view of their genetic and molecular heterogeneity despite sharing histological and etiological homogeneity.

Molecular Basis of Risk Factors

Genetic factors contributing to increased risk of carcinogenesis

The most important risk factor for developing head and neck cancer is tobacco with its effects linked to p53 mutations.^[1] Alcohol and betel nut ^[2],[3],[4] chewing have synergistic effect with tobacco. Tobacco smoke contains many known carcinogens of which benzo[a] pyrenediol epoxide,^[6] induces DNA adducts throughout the genome. These DNA damages are repaired by the human DNA repair machinery which includes nucleotide excision repair (NER) and base excision repair (BER)^{[7],[8],[9],[10]} pathways. Genetic polymorphisms ^[5] in the genes involved in NER ^{[11],[12],[13],[14],[15],[16]} such as ERCC-1 and XPD and in the genes involved in BER such as XRCC-1 and ADPRT may contribute to increased risk and susceptibility to head and neck squamous cell carcinoma (HNSCC).

Infections: Human papillomavirus-infected head and neck squamous cell carcinoma

Human papillomavirus (HPV) is a strictly epitheliotropic, double-stranded DNA virus that has been studied since 1980's in the etiopathogenesis of HNSCC.^{[17],[18],[19]} HPV-positive and HPV-negative tumors represent different clinicopathological and genetic/molecular entities.^[20] This subgroup is unique in that it has a favorable prognosis, affects the younger population, has a site predilection for the tonsils/oropharynx.^[21],[22] The oropharyngeal cancer increase began in the late 1970s and is attributed to increased rates of infection with high-risk HPVs secondary to changing sexual practices that are traceable to widespread use of oral contraceptives, reduced use of condoms, and freedom to have more sexual partners, without the fear of an unwanted pregnancy. The virus contains two oncogenes, E6 and E7, the expression of which inactivates p53 and retinoblastoma (RB), respectively, causing alterations of cell cycle regulation in the infected cells.

As HPV-related tumors seem to respond well to both chemotherapy and radiation, the question arises as to whether we are overtreating patients and exposing them to unnecessary long-term treatment-related toxicity. Trials are ongoing to determine how to treat these patients with maximal efficacy while limiting treatment-related toxicities. The role of vaccines in preventing HPV-related HNSCC-like cervical cancers, time can only prove.

Genetic cancer syndromes

There are many genetic cancer syndromes that have been postulated as contributing to increased risk of HNSCC such as Fanconi's anemia,^[23] Bloom syndrome, Ataxia Telangiectasia,^[25] and Xeroderma Pigmentosa,^[26] which are characterized usually by early age of onset of malignancy and specific and unusual patterns of clinical presentation and multiple malignancies in the same individual sometimes of different histologies. There are familial head and neck cancers ^[24] associated with inherited defects in CDKN2A locus ^[28] (also known as multiple tumor suppressor gene 1)^[27] and in hMDM2 regulator p14ARF. This relatively rare but a mysterious subset of patient population with young patients without known risk factors provide a valuable and rich area for studies at molecular level [Table 1].

Table 1: Classification of head and neck squamous cell carcinoma

Click here to view

Field Cancerization

The concept of field cancerization was first elucidated by Slaughter et al. in 1953^[29] in his classic paper. This concept formed the basis for the logical explanation for second primary tumors and local recurrences. Many years later, the concept was revisited in the molecular era, and molecular basis of multistep process of carcinogenesis was studied.

The concept can be summarized as the multistep process of patch-field carcinoma process [Figure 1] and [Figure 2].

Figure 1: Molecular multistep model of carcinogenesis

Click here to view

Figure 2: Integrated model of multi.step molecular carcinogenesis in head and neck squamous cell carcinoma.

Click here to view

Patch

The initial step is when normal stem cell acquires genetic alterations leading to the formation of clonal unit ^[30] of altered daughter cells known as the patch, which has mutations in TP53.^[32]

Field

The next logical and critical step is to acquire more genetic changes that give additional survival and proliferative advantage to these cells, leading to the formation of a field.

Tumor

Further clonal divergence leads to the development of tumors within a contiguous field of premalignant cells. The importance of this concept lies in the fact that these fields remain despite tacking the primary tumor. This results in second primary tumors or in local recurrences.^[31] Hence, it is vital to tackle the field as well during therapy and to keep under close surveillance.

Hallmarks of Cancer

The hallmarks of cancer ^[12] constitute the biological capabilities acquired by human tumors in their multi-step process of carcinogenesis. It forms the framework for rationalizing the complexities involved in neoplasia. Here, we review the most promising pathways, receptors, and proteins from this inventory, implicated in the initiation, promotion, and progression of human HNSCC with relation to each of these hallmarks of cancer [Figure 3].

Figure 3: Hallmarks of cancer.

Click here to view

Hallmark-1: Enabling replicative immortality

The key feature acquired by cancer cells to evade senescence and to acquire replicative immortality is to regulate the cell cycle.^{[33],[34],[35],[36],[37]}

HPV-negative head and neck squamous cell carcinoma: TP53, CCND1, and CDKN2A are established cancer genes in HPV-negative
HPV-positive head and neck squamous cell carcinoma: TP53 and the genes encoding the Rb family (comprising RB1,RBL1 [which encodes p107], and RBL2 [which encodes p130]) are established cancer genes in HPV-positive HNSCC
Ectopic expression of telomerase reverse transcriptase (TERT, the catalytic subunit of telomerase)
Cancer stem cells (CSCs): CSCs constitute a highly tumorogenic subpopulation of cells within the tumor (constituting <10% of the whole tumor)^[38] characterized by the ability of self-renewal, differentiation, and proliferation. They play a pivotal role in cancer progression, treatment failure, growth of primary tumor, and metastasis. They are postulated to play a role in treatment failures and recurrences after treatment. The important genes and transcription factors deciphered so far in the molecular biology of stem cells include NANOG (inhibitor of self-differentiation and chemotherapy resistance), OCT-4 (for self-renewal and pluripotency), BMI1 (in self-renewal), and Snail and Twist and Wnt signaling (in epithelial to mesenchymal transition, which is important in metastasis) and ABC (in drug efflux and chemotherapy resistance).

Thus, CSC plays a pivotal role in treatment resistance and in recurrence after therapy.^{[39],[40],[41]}

[Table 2] gives a summary of important genes/transcription factors considered important in CSC Biology [Table 2].

Table 2: Important factors in cancer stem cell biology

Click here to view

Hallmark-2: Changes in growth factor signaling: The epidermal growth factor receptor pathway

Epidermal growth factor receptor (EGFR) signaling plays an important role in carcinogenesis, progression, and treatment responses. In HNSCC, EGFR is overexpressed in up to 80–100% of tumors, some of the highest rates of any human carcinoma.^{[42],[43],[44]} There are regional differences among sites in the head and neck that express EGFR, with relatively lower levels associated with laryngeal tumors compared with those of the oral cavity and oropharynx.^[44]

When extracellular ligands bind to EGFR it leads to dimerization of receptors, which causes autophosphorylation, which in turn leads to the activation of many intracellular downstream oncogenic signal transduction pathways such as Ras, Raf, MAP-kinase-pathway, JAK-STAT, and PI3K/AKT pathways as depicted in flowchart below, which leads to increased cell proliferation, activation of angiogenesis, and inhibition of apoptosis.^{[45],[46],[47]}

Important features of EGFR overexpressing tumors are as follows:^[48],[49]

More advanced stage of disease
Poorly differentiated tumors
Poor chemo/targeted therapy sensitivity
Increased treatment resistance
Radiation sensitivity.

The prominent role that EGFR plays in HNSCC tumourogenesis has prompted intense research in the development of targeted therapies based on EGFR.^[50] The search for molecular predictive and prognostic factors based on EGFR is an area of active and intense investigation today [Table 3].

Table 3: Potential therapeutic targets based on EGFR

Click here to view

Insulin-like growth factor type-1 receptor

Insulin-like growth factor type-1 receptor is a transmembrane tyrosine kinase receptor, whose activation leads to intracellular signal transduction cascade activation, through Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase protein kinase, which leads to increased cell proliferation and resistance to apoptosis.^[51],[52] This is a potential therapeutic target for the future.

Hallmark-3: Insensitivity to growth inhibitory signals: The transforming growth factor-beta pathway

An important growth inhibitory pathway associated with HNSCC is the transforming growth factor-beta (TGF-β) pathway.

It acts through the TGF-β receptors ^[53] and then through the intracellular signal transduction mediators SMAD2 and SMAD3 and SMAD4,^[54],[55] which regulate target gene transcription and thus downregulates proliferation and increases apoptosis. TGF-β downregulation also activates the NF-KB pathway which provided survival signal to the cells.

Hallmark-4: Evading apoptosis: PI3K-PTEN-AKT

This is an important signal transduction pathway that is implicated in 10–20% of HNSCC. Besides activating PIK3CA mutations,^[56] inactivating mutations or deletions of PTEN have also been described that once activated cannot turn off the PI3K pathway.

Hallmark-5: Invasion and metastasis

HNSCC like all other classic solid tumors is associated with lymph node metastasis, which is an important prognostic factor. Metastatic dissemination requires extracellular matrix degradation, which requires the activation of a cascade of matrix metalloproteinases. The CSMD1 gene on chromosome 8p has been intensively studied for its involvement in the invasion and metastasis of especially in supraglottic laryngeal cancer.

Epithelial-to-mesenchymal transition

This is a particularly dangerous and pathological form of reprogramming of cells that leads to tissue invasion and metastasis, one of the most important hallmarks of malignancy. Epithelial-to-mesenchymal transition is the culmination of a series of transcriptional and translational events and modifications that lead to reprogramming of cells. Cells lose their cell-cell adherence through tight junctions/cadherins/desmosomes and acquire increasing cell mobility and become more migratory, thus leading to tissue invasion and metastasis.^{[57],[58],[59]} This has been shown to play a pivotal role in high-risk HNSCC, though its complete clinical significance is yet to be deciphered.^[60]

Hallmark-6: Angiogenesis

Tumor growth is usually limited by the requirement of oxygen and nutrient supply to the interior of the tumor and the elimination of catabolites from the tumor.^[61],[62] This requires growth factors like VEGF to induce sprouting of endothelial cells and new vessel formation to feed the tumor. There have been many studies that have linked VEGF expression by IHC to prognosis in HNSCC including a meta-analysis that reported a higher risk of.^[62] However, studies with adjustments for other confounders such as HPV status are needed.^[63] Anti-VEGF targeted therapies in pipeline included sunitinib, sorafenib, and bevacizumab, which are being explored in HNSCC, though conclusive evidence from studies is awaited.

Epigenetic Modification

Tumourogenesis need not always be due to direct damage to the genome. It could be due to changes in gene expression without altering the gene sequence. It could be due to the methylation of base sequences/modification of histone proteins by acetylation/ubiquitination or methylation. Hypermethylation of tumor suppressor genes has been studied as a probable mechanism of development of HNSCC without altering the genetic information/DNA sequence.^[64]

Driver and Passenger Genes in Head and Neck Squamous Cell Carcinoma-Candidate Genes/established Genes

HNSCC has a paucity of driver oncogenes, so targeting these pathways forms a critical challenge in the success of our therapeutic armamentarium against this malignancy ^[48] [Table 4].

Table 4: Driver and passenger genes in head and neck squamous cell carcinoma-candidate genes/established genes

Click here to view

Conclusions

It has been rightly said that HNSCC is a malignancy where we have no regimen of choice; instead, we have a choice of regimens. Hence, the success of therapy of such a genetically heterogeneous malignancy would lie in prompt identification of prognostic and predictive factors of therapeutic response at the molecular level; so that personalized and precision medicine can be provided and neither the good risk group is overtreated nor is the poor risk group undertreated. The integration of molecular diagnostics and the molecular risk–based approach to cancer treatment that is pathway-driven is the challenge for the years to come.

“Bench to bedside and back to bench” is the way forward in the era of molecular diagnostics and personalized precision medicine.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1.	Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:712-7.
2.	Zain RB, Gupta PC, Warnakulasuriya S, Shrestha P, Ikeda N, Axell T. Oral lesions associated with betel quid and tobacco chewing habits. Oral Dis 1997;3:204-5.
3.	Norton SA. Betel: Consumption and consequences. J Am Acad Dermatol 1998;38:81-8.
4.	Warnakulasuriya S, Trivedy C, Peters TJ. Areca nut use: An independent risk factor for oral cancer. BMJ 2002;324:799-800. [PUBMED]
5.	Hopkins J, Cescon DW, Tse D, Bradbury P, Xu W, Ma C, et al. Genetic polymorphisms and head and neck cancer outcomes: A review. Cancer Epidemiol Biomarkers Prev 2008;17:490-9.
6.	Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a] pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274:430-2.
7.	Wilson DM 3^rd, Bohr VA. The mechanics of base excision repair, and its relationship to aging and disease. DNA Repair (Amst) 2007;6:544-59.
8.	Hung RJ, Hall J, Brennan P, Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: A HuGE review. Am J Epidemiol 2005;162:925-42.
9.	Li C, Hu Z, Lu J, Liu Z, Wang LE, El-Naggar AK, et al. Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck. Cancer 2007;110:867-75.
10.	Cheng L, Sturgis EM, Eicher SA, Spitz MR, Wei Q. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer 2002;94:393-7.
11.	Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007;13:3855-9.
12.	Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
13.	Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, et al. XPD polymorphisms: Effects on DNA repair proficiency. Carcinogenesis 2000;21:551-5.
14.	Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, Ashok TD, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 2000;21:965-71.
15.	Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: Effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 1999;59:2557-61.
16.	Lei YC, Hwang SJ, Chang CC, Kuo HW, Luo JC, Chang MJ, et al. Effects on sister chromatid exchange frequency of polymorphisms in DNA repair gene XRCC1 in smokers. Mutat Res 2002;519:93-101.
17.	Gillison ML. Current topics in the epidemiology of oral cavity and oropharyngeal cancers. Head Neck 2007;29:779-92.
18.	Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-9.
19.	Syrjänen S. HPV infections and tonsillar carcinoma. J Clin Pathol 2004;57:449-55.
20.	Woods KV, Shillitoe EJ, Spitz MR, Schantz SP, Adler-Storthz K. Analysis of human papillomavirus DNA in oral squamous cell carcinomas. J Oral Pathol Med 1993;22:101-8.
21.	Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001;344:1125-31.
22.	Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: A meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:622-35.
23.	Lustig JP, Lugassy G, Neder A, Sigler E. Head and neck carcinoma in Fanconi's anaemia – Report of a case and review of the literature. Eur J Cancer B Oral Oncol 1995;31B: 68-72.
24.	Prime SS, Thakker NS, Pring M, Guest PG, Paterson IC. A review of inherited cancer syndromes and their relevance to oral squamous cell carcinoma. Oral Oncol 2001;37:1-16.
25.	Hecht F, Hecht BK. Cancer in ataxia-telangiectasia patients. Cancer Genet Cytogenet 1990;46:9-19.
26.	Keukens F, van Voorst Vader PC, Panders AK, Vinks S, Oosterhuis JW, Kleijer WJ. Xeroderma pigmentosum: Squamous cell carcinoma of the tongue. Acta Derm Venereol 1989;69:530-1.
27.	Sun S, Pollock PM, Liu L, Karimi S, Jothy S, Milner BJ, et al. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. Int J Cancer 1997;73:531-6.
28.	Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
29.	Slaughter DP, Southwick HW, SmejkaL W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953;6:963-8. [PUBMED]
30.	Braakhuis BJ, Tabor MP, Kummer JA. Perspectives in cancer research A genetic explanation of slaughter's concept of field cancerization: Evidence and clinical implications. Cancer Res 2003;63:1727-30.
31.	Braakhuis BJ, Tabor MP, Leemans CR, van der Waal I, Snow GB, Brakenhoff RH. Second primary tumors and field cancerization in oral and oropharyngeal cancer: Molecular techniques provide new insights and definitions. Head Neck 2002;24:198-206.
32.	Bedi GC, Westra WH, Gabrielson E, Koch W, Sidransky D. Multiple head and neck tumors: Evidence for a common clonal origin. Cancer Res 1996;56:2484-7.
33.	Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-23.
34.	Balz V, Scheckenbach K, Götte K, Bockmühl U, Petersen I, Bier H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003;63:1188-91.
35.	Opitz OG, Suliman Y, Hahn WC, Harada H, Blum HE, Rustgi AK. Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism. J Clin Invest 2001;108:725-32.
36.	Rheinwald JG, Hahn WC, Ramsey MR, Wu JY, Guo Z, Tsao H, et al. A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol 2002;22:5157-72.
37.	Smeets SJ, van der Plas M, Schaaij-Visser TB, van Veen EA, van Meerloo J, Braakhuis BJ, et al. Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways. Int J Cancer 2011;128:1596-605.
38.	Chen C, Wei Y, Hummel M, Hoffmann TK, Gross M, Kaufmann AM, et al. Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One 2011;6:e16466.
39.	Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999;397:164-8.
40.	Yu CC, Lo WL, Chen YW, Huang PI, Hsu HS, Tseng LM, et al. Bmi-1 regulates snail expression and promotes metastasis ability in head and neck squamous cancer-derived ALDH1 positive cells. J Oncol 2011;2011. pii: 609259.
41.	Clay MR, Tabor M, Owen JH, Carey TE, Bradford CR, Wolf GT, et al. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 2010;32:1195-201.
42.	Thariat J, Milas L, Ang KK. Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69:974-84.
43.	Citri A, Yarden Y. EGF-ERBB signalling: Towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
44.	Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666-72.
45.	Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74.
46.	Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial – INTACT 2. J Clin Oncol 2004;22:785-94.
47.	Grandis JR, Tweardy DJ. TGF-alpha and EGFR in head and neck cancer. J Cell Biochem Suppl 1993;17F: 188-91.
48.	Takes RP, Baatenburg de Jong RJ, Schuuring E, Litvinov SV, Hermans J, Van Krieken JH. Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell. Anticancer Res 1998;18:4793-800.
49.	Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6.
50.	Kim S, Grandis JR, Rinaldo A, Takes RP, Ferlito A. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck 2008;30:667-74.
51.	Ouban A, Muraca P, Yeatman T, Coppola D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 2003;34:803-8.
52.	Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004;11:793-814.
53.	Wang D, Song H, Evans JA, Lang JC, Schuller DE, Weghorst CM. Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck. Carcinogenesis 1997;18:2285-90.
54.	Huntley SP, Davies M, Matthews JB, Thomas G, Marshall J, Robinson CM, et al. Attenuated type II TGF-beta receptor signalling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination. Int J Cancer 2004;110:170-6.
55.	Qiu W, Schönleben F, Li X, Su GH. Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4. Cancer Lett 2007;245:163-70.
56.	Kozaki K, Imoto I, Pimkhaokham A, Hasegawa S, Tsuda H, Omura K, et al. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci 2006;97:1351-8.
57.	Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, et al. Epithelial – Mesenchymal and mesenchymal – Epithelial transitions in carcinoma progression. J Cell Physiol 2007;213:374-83.
58.	Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 2007;98:1512-20.
59.	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
60.	Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 2006;66:8210-8.
61.	Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49.
62.	Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: A meta-analysis. Clin Cancer Res 2005;11:1434-40.
63.	Fei J, Hong A, Dobbins TA, Jones D, Lee CS, Loo C, et al. Prognostic significance of vascular endothelial growth factor in squamous cell carcinomas of the tonsil in relation to human papillomavirus status and epidermal growth factor receptor. Ann Surg Oncol 2009;16:2908-17.
64.	Worsham MJ, Chen KM, Meduri V, Nygren AO, Errami A, Schouten JP, et al. Epigenetic events of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006;132:668-77.